ANKİLOZAN SPONDİLİTTE GÜNCEL TEDAVİ SEÇENEĞİ: TÜMÖR NEKROZ FAKTÖR ALFA ANTAGONİSTLERİ

Abdullah Erman Yağız, Nilgül Üstün
1.728 495

Öz


Ankilozan spondilit (AS), aksiyal iskelet,
entezis bölgeleri ve periferik eklemleri
etkileyen kronik, sistemik, inflamatuar bir
hastalıktır. AS tedavisinde farmakolojik
tedavi yanı sıra eğitim ve fizik tedavi gibi
farmakolojik olmayan tedavi metotları da
uygulanmaktadır. Farmakolojik ajanlardan
tümör nekroz faktör alfa (TNF-α)
antagonistleri diğer tedavilere yanıt
alınamayan hastalarda kullanılmaktadır.
Bunlar infliksimab, etanersept,
adalimumab ve golimumabdır. Bu ilaçlar
hem klinik hem de laboratuar parametreleri
üzerine etkinlik gösterebilmektedirler.
Ancak oluşabilecek yan etkiler nedeniyle
dikkatli olunması ve hastaların düzenli
takip edilmesi gerekmektedir.

Anahtar kelimeler: Ankilozan spondilit,
güncel tedavi, TNF-α antagonistleri


Tam metin:

PDF


Referanslar


Van Der Linden S, Van Der Hejide D, Braun J Ankylosing spondylitis. In: Harris ED,

Budd RC, Frestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (Editors)

Kelley’s textbook of rheumatology, 7. Baskı, Philadelphia:Elsevier Saunders, 2005:

-1141.

Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R.Comparison of serum

IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in

ankylosing spondylitis. Clin Rheumatol. 2007;26:211-5.

Reed MR, Taylor AL. Tumour necrosis factor inhibitors in ankylosing

spondylitis.Intern Med J. 2008;38:781-9.

Braun J, Sieper J. Ankylosing spondylitis.Lancet. 2007;369:1379-90.

Braun J, Van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez

E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman

RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP,

Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, Van

Drogen C, Van Royen B, Van der Heijde D. 2010 update of the ASAS/EULAR

recommendations for the management of ankylosing spondylitis. AnnRheumDis.

;70:896-904.

Van der Linden S. Issues in the treatment of ankylosing spondylitis with non-steroidal

anti-inflammatory drugs. Wien Med Wochenschr. 2008;158:195-9.

Poddubnyy D, Van der Heijde D. Therapeutic controversies in spondyloarthritis:

nonsteroidal anti-inflammatory drugs.Rheum Dis Clin North Am. 2012;38:601-11.

Bodur H, Sivas F, Yılmaz Ö, Özgöçmen S, Günaydın R, Kaya T Ataman Ş, Altan L,

Altay Z, Aydoğ E, Birtane M, Borman P, Soy Buğdaycı D, Bütün B, Çakırbay H,

Duruöz T, Gürer G, Hepgüler S, Kamanlı A, Kuru Ö, Küçükdeveci A, Nacır B, Ölmez

N, Rezvani A, Çörekçi Yanık B. Türkiye romatizma araştırma savaş derneği ankilozan

spondilit ulusal tedavi önerileri.Turk J Rheumatol. 2011;26:173-86.

Kabasakal Y, Kitapcioglu G, Yargucu F, Taylan A, Argin M, Gumusdis G. Efficacy of

SLZ and MTX (aloneorcombination) on thetreatment of active sacroiliitis in early

AS.Rheumatol Int. 2009;29:1523-7.

Khalessi AA, Oh BC, Wang MY. Medical management of ankylosing

spondylitis.Neurosurg Focus. 2008;24:E4.

Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new?Curr

Rheumatol Rep. 2012;14:422-7.

Machado MA, Barbosa MM, Almeida AM, de Araujo VE, Kakehasi AM, Andrade EI,

Cherchiglia ML, Acurciof de A. Treatment of ankylosing spondylitis with TNF

blockers: a meta-analysis.Rheumatol Int. 2013;33:2199-213.

Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R,

Landewe R, Rudwaleit M, Braun J; Assessment of Spondylo Arthritis international

Society. 2010 Up date of the international ASAS recommendations for the use of anti-

TNF agents in patients with axial spondyloarthritis.Ann Rheum Dis. 2011;70:905-8.

Brandt J, Marzo-Ortega H, Emery P. Ankylosing spondylitis: new treatment modalities.

Best Pract Res Clin Rheumatol. 2006;20:559-70.

Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H,

Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J. Treatment of

active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Lancet. 2002;359:1187-93.

Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun

J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy

Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis:

results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum.

;52:582-91.

Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S,

Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of

anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing

spondylitis over 5 years: evidence for different types of response.Ann Rheum Dis.

;67:340-5.

Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe

S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J.Persistent clinical efficacy

and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response

predicts long-term outcome. Rheumatology (Oxford). 2011;50:1690-9.

Braun J, Breban M, Maksymowych WP. Therapy for ankylosing spondylitis: new

treatment modalities. Best Pract Res Clin Rheumatol. 2002;16:631-51.

De Stefano R, Frati E, De Quattro D, Menza L, Manganelli S. Low doses of etanercept

can be effective to maintain remission in ankylosing spondylitis patients.Clin

Rheumatol. 2013. [Epubahead of print]

Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of

tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M,

Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of

etanercept treatment in patients with active ankylosing spondylitis.Arthritis Rheum.

;48:1667-75.

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term

outcome of patients with active ankylosing spondylitis with etanercept-sustaine

defficacy and safety after seven years. Arthritis Res Ther. 2013;15(3):R67.

Zochling J. Assessment and treatment of ankylosing spondylitis: current status and

future directions.Curr Opin Rheumatol. 2008;20(4):398-403.

Braun J, Sieper J. Biological therapies in the spondyloarthritides-the current

state.Rheumatology (Oxford). 2004;43:1072-84.

Van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA,

Mease PJ, Davis JC Jr; ATLAS Study Group.Adalimumab effectiveness for the

treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results

from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9.

Sieper J, Van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA,

Arora V, Pangan AL. Efficacy and safety of adalimumab in patients with nonradiographic

axial spondyloarthritis: results of a randomised placebo-controlled trial

(ABILITY-1).Ann Rheum Dis. 2013;72:815-22.

Sieper J, Van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early

response to adalimumab predicts long-term remission through 5 years of treatment in

patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:700-6.

Mittal M, Raychaudhuri SP. Golimumab and certolizumab: the two new anti-tumor

necrosis factor kids on the block. Indian J Dermatol Venereol Leprol. 2010;76:602-8.

Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S,

Hsia EC. Golimumab in patients with active rheumatoid arthritis despite

methotrexatetherapy: results through 2 years of the GO-FORWARD study extension. J

Rheumatol. 2013;40:1097-103.

Inman RD, Davis JC, Heijde DV, Diekman L, Sieper J, Kim SI, Mack M, Han J,

Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in

patients with ankylosing spondylitis: results of a randomized, double-blind, placebocontrolled,

phase III trial. Arthritis Rheum. 2008;58:3402-12.

Braun J, Baraliakos X, Hermann KG, Van der Heijde D, Inman RD, Deodhar AA,

Baratelle A, Xu S, Xu W, Hsu B. Golimumab reduces spinal inflammation in

ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE

study.Ann Rheum Dis. 2012;71:878-84.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.